Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Purespring Therapeutics Limited currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner. The portfolio is located in 1 distinct art unit. MCCORMICK, CATHERINE LYNN is the busiest examiner for the company. This examiner is responsible for 1 busiest examiner pending action. With only 1 pending office action, the company's current activity at the USPTO is highly focused. The use of 1 distinct art unit suggests a specific therapeutic or biological focus within the Biotechnology & Pharmaceuticals field.
MCCORMICK, CATHERINE LYNN manages the entirety of the pending workload. For practitioners, this indicates a single point of interaction for the company's current patent prosecution. The concentration of 1 distinct examiner and 1 distinct art unit means that the prosecution strategy is not divided across different USPTO groups. This centralized approach is common for entities with a single pending office action. MCCORMICK, CATHERINE LYNN is the sole individual responsible for the 1 busiest examiner pending action. The data confirms that the current patent efforts are confined to this specific examiner and art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCCORMICK, CATHERINE LYNN | 1 | 52.3% | +39.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19313174 | METHODS OF DELIVERING A VIRAL VECTOR TO A KIDNEY | MCCORMICK, CATHERINE LYNN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19313174 | METHODS OF DELIVERING A VIRAL VECTOR TO A KIDNEY | MCCORMICK, CATHERINE LYNN | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19313174 | METHODS OF DELIVERING A VIRAL VECTOR TO A KIDNEY | MCCORMICK, CATHERINE LYNN | 1638 | §101§103DP | Final Rejection | — | Pending | Aug 28, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPurespring Therapeutics Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Catherine Lynn Mccormick has the most, with 1 of Purespring Therapeutics Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
